These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11392447)

  • 1. Role of formulation vehicles in taxane pharmacology.
    van Zuylen L; Verweij J; Sparreboom A
    Invest New Drugs; 2001 May; 19(2):125-41. PubMed ID: 11392447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
    Gelderblom H; Verweij J; Nooter K; Sparreboom A
    Eur J Cancer; 2001 Sep; 37(13):1590-8. PubMed ID: 11527683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
    ten Tije AJ; Verweij J; Loos WJ; Sparreboom A
    Clin Pharmacokinet; 2003; 42(7):665-85. PubMed ID: 12844327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
    de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
    Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
    J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
    Vigano L; Locatelli A; Grasselli G; Gianni L
    Invest New Drugs; 2001 May; 19(2):179-96. PubMed ID: 11392452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.
    Tsallas A; Jackson J; Burt H
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):431-44. PubMed ID: 21069339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
    Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
    Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN; Gréen H; Litton JE; Friberg LE
    Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
    Ng SS; Figg WD; Sparreboom A
    Cancer Res; 2004 Feb; 64(3):821-4. PubMed ID: 14871806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
    Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam.
    Bravo González RC; Huwyler J; Boess F; Walter I; Bittner B
    Biopharm Drug Dispos; 2004 Jan; 25(1):37-49. PubMed ID: 14716751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.